Jamil Khurram 4

What Happened
Jamil Khurram, Chief Medical Officer of Galectin Therapeutics, received two equity awards on January 16, 2026: a 65,000-share option-style award and a 100,000 restricted stock unit (RSU) award. Both grants are reported as derivative awards with an acquisition price of $0, so there was no cash paid by the insider at grant.

Key Details

• Transaction date: 2026-01-16; Form 4 filed 2026-01-21 (appears timely given the MLK Day holiday on 1/19/2026).
• Award types and amounts: 65,000 (option-style vesting) and 100,000 RSUs; both reported as derivative grants, $0 per share at grant.
• Plan: Issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
• Vesting: Option-style award vests 25% on each of four scheduled dates (June 30, 2026; Dec 31, 2026; June 30, 2027; Dec 31, 2027). RSUs vest 100% on the earlier of Dec 31, 2026 or the signing of a partnership agreement.
• Conversion: RSUs convert into common stock on a one-for-one basis upon vesting.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Filing timeliness: Filed Jan 21, 2026; appears timely given the holiday-adjusted two-business-day filing requirement.

Context
These awards are compensation grants, not open-market purchases or sales, and therefore reflect standard equity-based pay rather than an immediate buy/sell signal. The option-style award vests over four installments; the RSUs may vest sooner if a partnership agreement is signed, at which point RSUs convert 1:1 into common shares. Such grants are common for executives and do not by themselves indicate intent to buy or sell shares.